Cancer

Visionary Holdings: Generative AI Leads the Efficiency Revolution, Reshaping the Future of FinTech and Biotechnology

TORONTO, Feb. 28, 2025 /PRNewswire/ -- In the context of the global economy's digital transformation, Artificial Intelligence (AI) has emerged…

10 months ago

NeuralCure AI Partners with Leading Medical Imaging Provider to Enhance AI-Powered Diagnostic Support for Physicians

AI-Driven Insights to Be Integrated with Life Imaging FLA's Full-Body CT Scan Services Through Their Upcoming 200 Location Expansion DENVER…

10 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the…

10 months ago

CHMP recommends EU approval of Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an…

10 months ago

Johnson & Johnson’s DARZALEX® (daratumumab) subcutaneous-based regimen receives positive CHMP opinion for patients with newly diagnosed multiple myeloma, regardless of transplant eligibility

If approved, daratumumab will be the only anti-CD38 available for all patient types across newly diagnosed multiple myeloma, cementing daratumumab…

10 months ago

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

-- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 --…

10 months ago

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s…

10 months ago

Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin…

10 months ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging…

10 months ago

LA FIRE VICTIMS CAN RELEASE SOME OF THE STRESS: NUCALM AND TONY ROBBINS JOIN FORCES TO GIVE BACK

NuCalm Donates One-Year Membership to their Mobile App to Help Families Heal from the Trauma of Loss and Displacement WILMINGTON,…

10 months ago